Embodiments of a computing device and methods of providing a cancer assessment for a patient are described. The method involves isolating a volume of a fluid from a fluid sample of the patient, the volume of fluid including at least one biomarker; adding at least a portion of the volume of fluid to a nanosensor comprising nanoparticles configured to capture the at least one biomarker and amplify signals emitted by the at least one biomarker during Raman spectroscopy; performing Raman spectroscopy on the volume of fluid on the nanosensor to produce a sample Raman spectrum having amplified signals indicating the presence of the at least one biomarker on the nanosensor; processing the sample Raman spectrum using data from template Raman spectra from known cancer samples; and based on the detected one or more cancer characteristics, providing the cancer assessment of the patient.

Embodiments of a computing device and methods of providing a cancer assessment for a patient are described. The method involves isolating a volume of a fluid from a fluid sample of the patient, the volume of fluid including at least one biomarker; adding at least a portion of the volume of fluid to a nanosensor comprising nanoparticles configured to capture the at least one biomarker and amplify signals emitted by the at least one biomarker during Raman spectroscopy; performing Raman spectroscopy on the volume of fluid on the nanosensor to produce a sample Raman spectrum having amplified signals indicating the presence of the at least one biomarker on the nanosensor; processing the sample Raman spectrum using data from template Raman spectra from known cancer samples; and based on the detected one or more cancer characteristics, providing the cancer assessment of the patient.

Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.

Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.

This invention provides nucleoside polyphosphate analogues each of which comprises a tag comprising a plurality of Raman-scattering moieties; compounds comprising said nucleoside polyphosphate analogs. This invention also provides nucleotide polymerases with one or more attached and/or conjugated noble metal nanoparticles, wherein the noble metal nanoparticles are surface-enhanced Raman spectroscopy (SERS) substrates thereby creating a region of enhanced sensitivity for surface enhanced Raman spectroscopy (SERS) within or adjacent to the polymerase. This invention also provides a surface with regions of enhanced sensitivity for surface enhanced Raman spectroscopy comprising interspersed rough or nanostructured noble metal surface. This invention also provides methods for determining the sequence of a single stranded DNA or RNA polynucleotide using one or more of nucleoside polyphosphate analogues, polymerase with noble metal nanoparticles, and surface with noble metal.

This invention provides nucleoside polyphosphate analogues each of which comprises a tag comprising a plurality of Raman-scattering moieties; compounds comprising said nucleoside polyphosphate analogs. This invention also provides nucleotide polymerases with one or more attached and/or conjugated noble metal nanoparticles, wherein the noble metal nanoparticles are surface-enhanced Raman spectroscopy (SERS) substrates thereby creating a region of enhanced sensitivity for surface enhanced Raman spectroscopy (SERS) within or adjacent to the polymerase. This invention also provides a surface with regions of enhanced sensitivity for surface enhanced Raman spectroscopy comprising interspersed rough or nanostructured noble metal surface. This invention also provides methods for determining the sequence of a single stranded DNA or RNA polynucleotide using one or more of nucleoside polyphosphate analogues, polymerase with noble metal nanoparticles, and surface with noble metal.

The purpose of the present invention is to provide a DNA transport control device having excellent reliability and durability, and a DNA sequencing device that uses the DNA transport control device. The present invention provides a DNA transport control device having a nanopore which allows for the passage of only the DNA strand of a single molecule, and a DNA sequencing device that uses the DNA transport control device. The DNA transport control device is characterized by the following: including a base material having openings and a thin film a block copolymer formed on the base material; the thin film including microdomains that are formed as a result of self-assembly of the block copolymer and that penetrate the thin film, and a matrix surrounding the microdomains; and the nanopore being formed from one opening in the base material and a single microdomain.

The purpose of the present invention is to provide a DNA transport control device having excellent reliability and durability, and a DNA sequencing device that uses the DNA transport control device. The present invention provides a DNA transport control device having a nanopore which allows for the passage of only the DNA strand of a single molecule, and a DNA sequencing device that uses the DNA transport control device. The DNA transport control device is characterized by the following: including a base material having openings and a thin film a block copolymer formed on the base material; the thin film including microdomains that are formed as a result of self-assembly of the block copolymer and that penetrate the thin film, and a matrix surrounding the microdomains; and the nanopore being formed from one opening in the base material and a single microdomain.

Embodiments of a computing device and methods of providing a cancer assessment for a patient are described. The method involves isolating a volume of a fluid from a fluid sample of the patient, the volume of fluid including at least one biomarker; adding at least a portion of the volume of fluid to a nanosensor comprising nanoparticles configured to capture the at least one biomarker and amplify signals emitted by the at least one biomarker during Raman spectroscopy; performing Raman spectroscopy on the volume of fluid on the nanosensor to produce a sample Raman spectrum having amplified signals indicating the presence of the at least one biomarker on the nanosensor; processing the sample Raman spectrum using data from template Raman spectra from known cancer samples; and based on the detected one or more cancer characteristics, providing the cancer assessment of the patient.

Embodiments of a computing device and methods of providing a cancer assessment for a patient are described. The method involves isolating a volume of a fluid from a fluid sample of the patient, the volume of fluid including at least one biomarker; adding at least a portion of the volume of fluid to a nanosensor comprising nanoparticles configured to capture the at least one biomarker and amplify signals emitted by the at least one biomarker during Raman spectroscopy; performing Raman spectroscopy on the volume of fluid on the nanosensor to produce a sample Raman spectrum having amplified signals indicating the presence of the at least one biomarker on the nanosensor; processing the sample Raman spectrum using data from template Raman spectra from known cancer samples; and based on the detected one or more cancer characteristics, providing the cancer assessment of the patient.